Eli Lilly reports positive Phase 3 data for retatrutide, with patients achieving 20.8% weight loss over 80 weeks, strengthening the company's competitive position in the diabetes and obesity treatment landscape.
Positive Phase 3 trial results for retatrutide showing substantial weight loss and A1C reduction could significantly boost Lilly's obesity and diabetes franchise.
Eli Lilly's experimental drug retatrutide demonstrated significant efficacy in the TRIUMPH-2 Phase 3 trial, helping patients with obesity and type 2 diabetes lose an average of 49.6 pounds. The results underscore the drug's potential to disrupt the metabolic health market as more than half of participants dropped below obesity BMI thresholds.
Participants with obesity and type 2 diabetes achieved an average weight loss of 49.6 pounds, or 20.8% of their body weight, over an 80-week period.